Galway’s position as one of Europe’s leading centres for medical technology innovation recently received another major endorsement with the announcement that Boston Scientific is to invest €75 million in expanding its research and development capabilities in the city.
The significant investment, unveiled this Spring represents not only a major milestone for the global healthcare giant, but also a substantial boost for the wider regional economy and Ireland’s thriving MedTech sector.
The development will further strengthen Boston Scientific’s Galway operation as a global hub for cardiovascular innovation, while reinforcing the West of Ireland’s growing reputation as a centre for advanced research, engineering excellence, and high-value manufacturing.
Supported by the Irish Government through IDA Ireland, the project will see the creation of purpose-built laboratories and enhanced R&D facilities designed to accelerate the development and testing of next-generation medical technologies. The expanded campus will support a broad range of programmes across structural heart therapies, cardiovascular treatments, and endoscopy, while also driving innovation in rapidly emerging fields such as heart failure therapies and renal denervation technologies.
For Galway, the announcement has been widely welcomed as a powerful vote of confidence in the region’s talent base, educational infrastructure, and long-established MedTech ecosystem. The investment is expected to generate significant economic activity, not only within Boston Scientific itself but across the wider network of local suppliers, service providers, construction firms, technology companies, and research institutions that support the industry.
Strong signal
At a time when regions across Europe are competing aggressively for high-value foreign direct investment, Boston Scientific’s decision to deepen its presence in Galway sends a strong signal internationally about the city’s attractiveness as a location for innovation-led enterprise.
Minister for Education and Youth Hildegarde Naughton described the investment as a clear demonstration of confidence in Galway and its skilled workforce.
“The decision by Boston Scientific to invest again in Galway shows real confidence in the talent and infrastructure available here,” she said. “The importance of R&D and innovation to Ireland’s economy cannot be overstated. It is achieved through a strong partnership between industry, Government and IDA Ireland and has acknowledged that Galway is now an internationally recognised MedTech hub.”
The announcement has particular significance for the local economy because of the central role Boston Scientific already plays in employment and economic activity across the region. The company has operated in Ireland for more than three decades and today employs over 7,000 people across Galway, Cork, and Clonmel. Its Galway facility has become one of the company’s most strategically important international sites, producing millions of life-saving medical devices annually for global markets.
Among the products manufactured and developed in Galway are drug-coated devices, vascular balloons, and heart and oesophageal stents—technologies that are used worldwide to treat conditions including cardiovascular disease, oesophageal cancer, and stroke risk.
Beyond direct employment, the latest expansion is expected to create substantial indirect economic benefits throughout the West of Ireland. Large-scale investments of this nature typically generate increased demand across construction, engineering services, logistics, hospitality, professional services, and technology support sectors. The development will also strengthen collaboration opportunities with local universities and research institutions, helping to further cultivate a pipeline of highly skilled graduates in engineering, science, and technology disciplines.
Industry observers note that R&D investments often have a particularly strong long-term economic impact because they anchor highly specialised, knowledge-intensive work within a region. This creates sustainable, high-value employment while also fostering innovation networks that can support start-ups and indigenous enterprises.
Boston Scientific executives emphasised that Galway’s highly skilled workforce and collaborative ecosystem played a major role in the company’s decision to continue investing in the region.
“We are seeing strong momentum across our cardiovascular business, and this investment reflects the important role the Galway site plays in that progress,” said Lance Bates, Executive Vice President and President of Interventional Cardiology and Vascular Therapies at Boston Scientific. “The local team is delivering complex, highly collaborative work that is advancing meaningful innovation for patients.”
He added that the strength of the Galway operation, combined with the support of the Irish Government and IDA Ireland, gives the company confidence to continue expanding its presence in Ireland.
Confidence
IDA Ireland also hailed the announcement as further evidence of Ireland’s global leadership in medical technology innovation. Rachel Shelly, Global Head of Life Sciences at IDA Ireland, said the investment reinforces Galway’s status as one of the world’s leading MedTech clusters.
“For more than 30 years, Boston Scientific has invested in advanced manufacturing and innovative technologies in Ireland, benefiting patients, communities and ecosystems locally and globally,” she said.
The latest announcement adds further momentum to Galway’s emergence as a powerhouse for advanced manufacturing and life sciences. Alongside a growing cluster of international healthcare and technology companies, the city has developed a strong reputation for research excellence, engineering talent, and innovation-driven enterprise.
For the local economy, Boston Scientific’s latest expansion represents far more than a capital investment. It is a reaffirmation of Galway’s international competitiveness, a catalyst for future growth, and another important step in securing the region’s position at the forefront of global medical technology innovation.
